Adverse events number of participants hospitalised during the trial · children with cystic fibrosis
Summary of findings: Zinc supplementation showed no clear difference in adverse events number of participants hospitalised during the trial compared with placebo (moderate certainty).
1 finding from 1 review
QoL · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (% predicted): mean change from baseline · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
Summary of findings: garlic supplementation showed no clear difference in respiratory function change from baseline in % predicted FEV1 compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (L) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (% predicted) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Time to next exacerbation · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum density: change in P aeruginosa sputum density (log1₀ CFU/g) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Quality of life: change in CFQ‐R score from start of treatment · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus
It is very uncertain whether levofloxacin changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with standard treatment (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cure · people with endocarditis due to Staphylococcus aureus in drug abusers
Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… may leads to lower cure compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (low certainty).
1 finding from 1 review
Adverse events · people with endocarditis due to Staphylococcus aureus in drug abusers
It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).
1 finding from 1 review
Congestive heart failure · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found